Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Patient experience at the forefront as the UAE healthcare market continues to grow
1st GCC Patient Experience Summit (18 - 19 September 2017) organized by Fleming.
ABU DHABI, March 28, 2017 - The UAE healthcare market is expected to grow by 7% from 2015 to 2020, propelled by medical tourism and a higher than ever demand for new facilities & technologies. Together with strong government funding and support, the UAE will no doubt be the front-runner in developing the best care and wellness for exceptional patient experience.
Patient experience elevation has become one of the top five priorities for healthcare organizations for the coming years. Like other industries, healthcare is facing new challenges generated by financial profitability, rising competition, increasing demand of high-quality care experience, and disruptive technologies offering omni-channel interactions. The ability to adopt innovative approaches to keep patients connected to the ever-changing healthcare ecosystem is highly crucial for business sustainability.
“To be successful in the new era of challenging and promising healthcare, organizations will have to take engagement to a new level and consider patients central to the care team. Strategic focus on patient feedback all along the care continuum will be essential to continually improve the health of populations. Wellness and prevention are key. We are moving from an era of treating disease to engaging patients in healthy behaviours that maintain their highest quality of life,” Samer Ellahham, Chief Quality Officer at Sheikh Khalifa Medical City, stressed out the importance of patient-centred care.
“Patient engagement starts with giving patients the tools they need to understand what makes them sick, how to stay healthy, and what to do if their conditions get worse. It means motivating and empowering patients to work with clinicians - to be active participants in their care by asking questions, knowing their medications and medical history, bringing friends or relatives to appointments for support, and learning about care that may be unnecessary,” he added.
Mr. Samer Ellahham will chair the 1st GCC Patient Experience Summit (18 - 19 September 2017) organized by Fleming. This region’s only forum dedicated to patient experience will feature CEOs, Patient Experience Directors and Chief Quality Officers from organizations such as HAAD, DHA, Cleveland Clinic, Hamad Medical Corporation, King Fahad Medical City and many others.
Participants will hear from award-winning healthcare providers on their excellence journey. Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, will introduce DHA's strategy 2016-2021 on patient/family-centric delivery of care and the launch of the ‘Dubai Health Experience’ as a tool to drive the national agenda of medical tourism through enhanced patient experience delivery.
Complementing the national pursuit of happiness, Dr. Wafa, Special Advisor of Dubai the Model Centre at the Executive Council, Government of Dubai & Dr. Ali Azzawi, City Experience Advisor at the Smart Office Dubai will outline the importance of patient empowerment and experience mapping for offering tailor-made, exceptional patient/family-centric care.
Themed “Transforming patient experience: Energize, empathize and engage,” the summit aims to offer access to a unique learning opportunity that sets the tone for establishing excellence benchmarks, effective communication and leadership strategies in customized care delivery.
For more information about the 1st GCC Patient Experience Summit, visit the link below:
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.